## ORIGINAL JAP3 Rec'd PCT/PTO 23 DEC 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES			ATTORNEY'S DOCKET NUMBER Le A 36 769				
DESIGNATED/ELECTED OFFICE (DO/EO/US)		U.S. APPLICATIONINO. (If known, see 37 CER 15)					
CONCERNING A SUBMISSIO		ON UNDER 35 U.S.C. 371	not assigned U/561884				
INTERNA	TIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
TITLE OF	PCT/EP04/006682	June 21, 2004 06/21/04	July 2, 2003 07/02/03				
TITLE OF INVENTION AMIDE-SUBSTITUTED 1,2,4-TRIAZIN-5(2H)-ONES FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES							
APPLICA	APPLICANT(S) FOR DO/EO/US						
Applicant	t herewith submits to the United Sta	Flessner, et al. ates Designated/Elected Office (DO/EC	O/US) the following items and other information:				
	Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:  1.   This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.						
2. 🗆 -	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.						
3. 🗶 -	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4. 🗶	The US has been elected (Article 31).						
5. 🗶	A copy of the International Application as filed (35 U.S.C. 371(c)(2))						
	a. 🔀 is attached hereto (required only if not communicated by the International Bureau).						
	b.  has been communicated by	the International Bureau.					
	c. is not required, as the applic	cation was filed in the United States Receivi	ing Office (RO/US).				
6. 🗶	An English language translation of the	e International Application as filed (35 U.S.C	C. 371(c)(2)).				
	a. is attached hereto.						
_	b.  has been previously submit	ted under 35 U.S.C. 154(d)(4).					
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
	a. are attached hereto (required only if not communicated by the International Bureau).						
	b. have been communicated	b. have been communicated by the International Bureau.					
	c. have not been made; howe	ever, the time limit for making such amendn	nents has NOT expired.				
	d. 🗶 have not been made and will not be made.						
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
Items	11 to 20 below concern document(s	) or information included:					
11. 🗶	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.					
12. 🔲	An assignment document for recording	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13.	A preliminary amendment.						
14.	An Application Data Sheet under 37 0	An Application Data Sheet under 37 CFR 1.76.					
15.	A substitute specification.						
16.	A power of attorney and/or change of	address letter.					
17.	A computer-readable form of the sequ	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.					
18.	A second copy of the published Intern	A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
19. 🗀	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).  1) Certificate of Mailing under 37 C.F.R. 1.10; and						
20.	Other items or information: 2) Itemized Return Receipt Postcard.						

Inis collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

Date of Deposit: 12/23/05

Express Mail Label No.: E0915483851US

## ORIGINALIAP29 Noc'd PCT.PTO 23 DEC 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPOCATION NO. (ILLATOWN, SEP 370 FR 1.5)			INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER		
not assigned			PCT/EP04/006682		Le A 36 769		
21. The followi	ng fees are submitted:	Applicant use	Office use only				
🗶 a) Basic na	ational fee	\$ 300.00					
b) Examination fee\$200.00			\$ 200.00				
X c) Search fee\$500.00				\$ 500.00			
TOTAL OF ABOVE CALCULATIONS = \$1000.00					\$ 1,000.00		
Additional f	Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence						
listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
Total Sheets Extra sheets Number			r of each additional 50 or fraction RATE of (round up to a whole number)				
- 100 =	<b>-0-</b> /50 ≈			x \$250.00	s		
Comphania	00.00 (*********************************	-16	Alam tatandhan 00 mmh d		<del> </del>		
	30.00 for furnishing the or date (37 CFR 1.492(e)).	ath or declara	tion later than 30 months from	m the earliest	\$		
CLAIMS	NUMBER FIL	.ED	NUMBER EXTRA	RATE	\$		
Total claims	. 6	- 20 =	n/a	x \$50.00	\$		
Independent clai	ims 4	- 3 =	-1-	x \$200.00	\$ 200.00		
MULTIPLE DEP	ENDENT CLAIM(S) (if ap	plicable)		+ \$360.00	\$		
			TOTAL OF ABOVE O	ALCULATIONS =	\$ 1200.00		
Applicant of by 1/2.	laims small entity status.	See 37 CFR	1.27. The fees indicated abo	ve are reduced	\$		
	· · · · · · · · · · · · · · · · · · ·		<u> </u>	SUBTOTAL =	\$ 1200.00		
	of \$130.00 for furnishing thate (37 CFR 1.492(f)).	he English tra	instation later than 30 months	s from the earliest +	\$		
TOTAL NATIONAL FEE = \$ 1200.00							
	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property						
		\$ 1200.00					
Amount to be refunded:						S	
	Amount to be charged					S	
			to cover the above				
	charge my Deposit Acco		3-3372 in the amount of \$	1200.00 to	cover the above fees.		
	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3372. A duplicate copy of this sheet is enclosed.						
	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
Restrate A Strain							
Jeffrey M. Greenman Bayer Pharmaceuticals Corporation				/ SIGNATURE	SIGNATURE  Barbara A. Shimei  NAME		
400 Morgan Lane							
West Haven, CT 06516				NAME			
				29, 862	ION ALL MADED	·	
				REGISTRAT	ION NUMBER		

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Flessner, et al.

Serial No.: [to be assigned] National Stage Filing of PCT/EP04/006682

Filed: herewith

For: AMIDE-SUBSTITUTED 1,2,4-TRIAZIN-5(2H)-ONES FOR THE TREATMENT OF CHRONIC

**INFLAMMATORY DISEASES** 

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereb	y certify that the attached correspondence comprising:				
	Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE]				
	Application Data Sheet under 37 C.F.R. 1.76				
Ø	Preliminary Amendment				
	Original oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))				
	English Translation of the Application (35 U.S.C. 371(c)(2))				
	Copy of the International Application as filed (35 U.S.C. 371(c)(2))				
	Copy of Published International Application, Number WO 2005/003118 A1				
	Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of:  1) Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b)(2)  2) Form(s) PTO/SB/08A-B [substitute for form 1449/PTO] (37 C.F.R. 1.98(a)(b))  3) Copies of Cited References (37 C.F.R. 1.98(d))				
	Other:				
	Itemized Return Receipt Post Card				
is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number					

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

/2/23/05 Date Maxella Chandlaung
Signature of Person Certifying / Mariellen Chapdelaine